EU Taxus Approval, Passive Coating Option Expand Boston Scientific’s Reach
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific projects that European conversion rates from bare-metal to drug-eluting stents will range 20-50% in 2003, as reimbursement trends improve